Canaccord Genuity Downgrades InterMune Inc. (ITMN) to Hold; Closer Look at Esbriet EU Launch
Tweet Send to a FriendGet Alerts ITMN Hot Sheet
Price: $9.58 -3.82%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade ITMN Now!
Canaccord Genuity downgraded InterMune Inc. (NASDAQ: ITMN) from Buy to Hold with a price target of $11.00 (from $15.00).
Analyst, Ritu Baral, said, "Lowering rating, price target on lower EU Esbriet (pirfenidone) sales prospects. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We still see good Esbriet EU potential (despite price concerns) and encouraging 2012 adoption. Our worldwide peak sales estimate is $1.97B in 2025."
"Q3, like Q2, likely to be weak, but patient number trends positive: logistical challenges plausible, may be addressable. We think the challenges of higher than expected patient drop-offs, legacy triple therapy patients, and IQWiG effect are all issues that ITMN may be able to address with an increased (optimized) sales/marketing push."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $9.91 yesterday, with a 52 week range of $9.66-$36.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Lowering rating, price target on lower EU Esbriet (pirfenidone) sales prospects. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We still see good Esbriet EU potential (despite price concerns) and encouraging 2012 adoption. Our worldwide peak sales estimate is $1.97B in 2025."
"Q3, like Q2, likely to be weak, but patient number trends positive: logistical challenges plausible, may be addressable. We think the challenges of higher than expected patient drop-offs, legacy triple therapy patients, and IQWiG effect are all issues that ITMN may be able to address with an increased (optimized) sales/marketing push."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $9.91 yesterday, with a 52 week range of $9.66-$36.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Baird Downgrades Titan Machinery (TITN) to Neutral
- BMO Capital Downgrades Nordson (NDSN) to Market Perform
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
